Menu
Menu
Sun Pharma acquires US-based Checkpoint Therapeutics for Rs 3,084 crore ($355 million), bolstering its oncology portfolio with FDA-approved UNLOXCYT for advanced skin cancer. The deal enhances global access to innovative cancer treatments and aligns with Sun Pharma’s strategy to expand in high-growth specialty therapies. Expected to close by June 2025.
Eris Lifesciences vends the entire interest it holds in the deadweight of two components for Therapeutics Ltd. to Eris for Rs 861.9 crore, thus connecting up with its core business growth, which is a strategic focus.
Introduction Piramal Enterprises Ltd., a leading financial services and pharmaceutical conglomerate, has recently been in the spotlight after receiving a significant GST demand notice. The company disclosed a goods-and-services-tax (GST) […]
Anupam Rasayan has partnered with Elementium Materials to supply specialty chemicals for electric vehicle (EV) batteries, with supply set to begin by the end of fiscal 2026. The deal could generate up to USD 450 million in sales, marking a significant step for Anupam Rasayan in the growing green energy sector.
Pfizer and Mylan have formed a strategic marketing and supply partnership for two key medications, Ativan and Pacitane. This collaboration aims to expand global access to treatments for anxiety disorders and Parkinsonism, ensuring broader availability for patients in need.
Healthcare Global Enterprises has posted a strong 22.46% increase in net profit and an 18.89% rise in sales for the December 2024 quarter. Despite a slight dip in operating margins and a drop in profit before tax, the company’s growth trajectory remains impressive, signaling its strong position in the healthcare sector.
Shilpa Medicare's Nor Ursodeoxycholic Acid Tablets 500 mg offer a promising new treatment for Non-Alcoholic Fatty Liver Disease (NAFLD). With Phase 3 trial results showing significant improvements in liver function and fibrosis reversal, this innovative therapy could become a new standard of care for millions of NAFLD patients.
Piramal Enterprises has secured approval to raise Rs 450 crore by issuing non-convertible debentures (NCDs). This strategic move aims to strengthen its financial position and support future growth. In this blog, we explore the details of the NCD issuance, the company’s strong recovery in Q3 FY25, and what it means for investors moving forward.
Lupin and Natco Pharma have received USFDA approval for Bosentan Tablets for Oral Suspension, a generic treatment for pediatric patients with pulmonary arterial hypertension (PAH). This approval provides an affordable option for improving exercise capacity and quality of life for children suffering from PAH.
Glenmark Pharmaceuticals and Cosmo Pharmaceuticals have received MHRA approval for Winlevi, a topical treatment for acne vulgaris in patients aged 12 and older. This marks a significant step in expanding access to effective acne care across the UK, Europe, and South Africa.